Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new study reveals best window for second heart procedure

NCT ID NCT04918030

Knowledge-focused Sponsor: Xiamen Cardiovascular Hospital, Xiamen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 1,586 heart attack patients who had multiple blocked arteries. After opening the main blockage, doctors compared doing a second procedure to fix the other blockages either early (within a few days) or later (weeks after). The goal was to see which timing better prevented future heart problems like death, another heart attack, or needing more procedures. The results help doctors decide the best timing for complete treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,586 people

The number who actually took part.

Started

Feb 2021

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures; * Established indication to PPCI according to the guidelines of American Heart Association and American College of Cardiology; * Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) with MVD after successful revascularization of the culprit artery; * De novo coronary lesion, * TIMI Flow 3 ( Cases with TIMI flow 2 need to perform angiographic again in 24h ensured TIMI flow 3 for enrolling case )after revascularization of the culprit artery, residual stenosis ≤20% and no coronary dissection greater than or equal to type C leading to (threatening) vessel closure. * At least one non-culprit coronary stenosis ≥ 80% and accompanied by QFR ≤0.8 in a vessel with a lumen diameter ≥2.5; Exclusion Criteria: * Age \<18 yr and \>80 yr; * Cardiac shock, multiple organ failure, cerebral hemorrhage, severe aortic stenosis and myocardial infarction complications(cardiac rupture, ventricular septal rupture and papillary muscle rupture); * Killip classification \>3, cardiognic shock, shore-infarction of culprit artery after emergency PCI in 24 hours; * Previous documented allergic reaction to drug and device of this study; * Planned major surgery within 6 weeks in which impact DAPT; * Participation in another clinical study, interfering with this protocol Uncertain; * Life expectancy \< 1 year; * Any condition likely to interfere with study processes including follow-up visits or increase of risk accessed by researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ami patients with multivessel disease, staged pci are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ami patients with multivessel disease, staged pci Multi vessel coronary artery disease Percutaneous coronary intervention STEMI

Contacts and locations

Locations

  • Xiamen Cardiovascular Hospital Xiamen University

    Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.